X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

BLCM

Closed

Bellicum Pharmaceuticals Inc

0.0747
-0.0054 (-6.74%)
Last Update: 04 Mar 2024 22:59:00
Yesterday: 0.0801
Day's Range: 0.0717 - 0.09
Send
When Written:
 
0.33
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops cellular immunotherapies for various types of cancers and other serious diseases. The company’s lead product candidate, BPX-601, is a CAR-T cell therapy that targets solid tumors. Bellicum’s other product candidates include BPX-603, a dual-switch CAR-T cell therapy for prostate cancer, and BPX-701, a TCR-T cell therapy for solid tumors. The company is also developing a platform technology called GoCAR-T, which allows for the control of CAR-T cells in vivo. Bellicum Pharmaceuticals was founded in 2004 and is headquartered in Houston, Texas.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X